The Ethics of Personalized Medicine: A Philosopher’s Perspective

Last Updated on

March 1, 2014 – Below please find an article just published in Medscape Oncology News. Since in the age of personalized or individualized medicine, personalization or individualization is so personal or individual to each one of the readers of this blog, I thought it worthwhile to make available to you this philosophers view on the topic. Enjoy reading, and draw your own personal or individual conclusions. (May I add that I copied and pasted the article in its entirety from Medscape site, and are copyrights are entirely with Medscape. I left the list of references, which can be easily found at the site of the original article).

Start of Article


It is a standard joke that when philosophers are asked to give a perspective on a topic, they first of all ask what it means and make no further progress. When it comes to personalized medicine, however, the question of meaning is very important insofar as our understanding of what is involved informs our understanding of the ethical issues. [1] This is critical, especially as the way issues are presented affects the expectations of patients. ‘Personalization’ suggests association with an individualist paradigm in ethics, although it may emerge that what is envisaged is more accurately described, at least in some cases, as stratification of the patient population into, for example, good or poor responders to a particular drug. Alternatively, patients may be divided into groups according to their disease type as more is learned about, for example, cancer subtypes. The prospects of increasing use of whole-genome sequencing (WGS), however, may make personalization a reality in a stronger sense.

The central idea of pharmacogenomics, that information about the variation in genetic make-up between individuals is relevant to prescription of drugs, introduced a specific sense to the concept of ‘personalization’ in which personalization became associated with a person’s genomic information. The ethical argument supporting this was the need to reduce the incidence of mortality and morbidity resulting from adverse drug responses. Personalized prescribing for a patient could be genetically informed, not only in relation to the choice of drug, but also in regards to dosage, thus minimizing the potential harm of inappropriate prescribing for a particular patient. Patients could be subdivided into those who could, and those who could not, tolerate a specific substance.

With the advent of WGS, the possibility of ‘tailoring’ medical advice and treatment to the individual throughout a lifetime becomes, at least, an in-principle possibility, although the term ‘tailoring’ was used by the UK Department of Health in 2003, before WGS was on the horizon. [2] The use of the tailoring metaphor gives a much stronger sense to personalization: all the multiple variations between individuals could be taken into account. In the clothing industry, there is a distinction between clothes tailored for the individual and those ready to wear for the mass market, and it might be tempting to think that this mirrors the distinction between personalized and blockbuster approaches to pharmaceuticals. However, within tailored clothing there is also a distinction between ‘bespoke’ and ‘made to measure’. Whereas ‘bespoke’ clothes are created without the use of a pre-existing pattern, ‘made to measure’ alters a standard-sized pattern to fit the customer. The move from genetic testing to WGS arguably suggests a move from ‘made to measure’ to ‘bespoke’. There is a caveat here, however, and that is that the word ‘bespoke’ comes from ‘bespeak’, which suggests that the individual is in control of the process. This may be where the analogy between personalized medicine and tailoring breaks down.

It is important not to overlook the fact that, although the ethical argument for personalized medicine was initially made to prevent adverse drug reactions (deeming it uncontroversial from that point of view), once a richer version of tailoring appears, attention also increasingly turns to benefits and to issues of equity in access. [3] The questions then are not only ‘how can we prevent harm to this person?’, but ‘how can we maximise the benefit?” and ‘how can we achieve justice in distribution?’ For example, suppose information emerges that, in relation to the prescription of a very expensive drug for cancer, some people may achieve a life extension of only a couple of weeks, while others may benefit with 2 years extra life. [4] It is not clear what criteria would be appropriate in such a situation. From one point of view, it might be argued that despite the variation in benefit, each person is entitled to receive the drug. From another, it might be argued that prescribing should be performed in order to maximize benefit.

There are also issues of international distribution to consider. Daar and Singer’s classic piece on pharmacogenomics and genetic ancestry argued eloquently against a situation in which the benefits of personalized medicine not only reinforced an individualistic ’boutique-style’ model of healthcare, but also operated to the disadvantage of less developed countries. [5] They argued a case for the possible benefits of ‘drug resuscitation’ in relation to products that had been taken off the market in the west, but which could also be beneficial in settings where the population had relevantly different genetic factors. [5]

Issues of equity impact strongly on public perceptions. When a new technology is introduced, there are always questions, not only relating to whether there are any new ethical issues, but also whether there are any public perception issues that might be challenging. This might be the case, for example, where personalization or stratification coincides with other ways of dividing up the population that might, historically, coincide with discrimination, such as racial or ethnic categories.

Some of the worries about personalized medicine arise in connection with its implementation. The rise of companies offering direct-to-consumer tests, for example, has led to criticisms over how the results might be interpreted, conveyed and misused. There are also concerns about what tests are offered, and the time at which tests may be offered. While it may be considered acceptable for an autonomous adult to decide to undertake genetic testing, there are different considerations relating to WGS at birth or even prenatally, for the purposes of personalized predictive medicine. [6] There is a view that prenatal genetic testing will become the standard of care. [7] However, over the past 15 years or so, the argument for a right not to know genetic information about oneself has been advanced, on the grounds that such knowledge may change one’s whole perception of one’s future life for the worse. [8] If widespread sequencing becomes the norm, to remain in ignorance may cease to be an option, and yet we should not necessarily think that knowledge here brings greater autonomy. The person ‘bespeaking’ the test is not identical with the one tested. There are also issues about the extent to which a genetic counseling model can be transferred to the new possibilities, or whether a consumer model is more appropriate.

For those who do want genetic testing and are prepared to pay for it, the price is falling, which may alleviate some of the concerns about access, but there are nevertheless concerns about control of the resulting data.

The promise of personalized medicine offers real exciting possibilities, and the language of personalization is becoming more than a rhetorical device: implementation is more complicated, partly because of the complexity of the mass of information emerging and partly because of concerns about implementation.


End of Article

Tags: , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Key modifier found in genetic deletion related to neurodevelopmental disorders February 14, 2020
    Neurodevelopmental disorders, including schizophrenia and autism, likely result from complex interactions that modify the effects of individual genes. In a new study, researchers evaluated the effects of over 300 pairwise knockdowns—reducing the expression of two genes simultaneously—of the fruit fly versions of genes located in a region of human chromosome 3 that, when deleted, has […]
  • Stress in small children separated from their parents may alter genes February 14, 2020
    Experts in the emotional needs of small children say increased levels of the stress hormone cortisol in babies and small children who are separated from their parents, especially their mothers, could have a long-term genetic impact on future generations. In a commentary published by the Journal of the Royal Society of Medicine, the authors say […]
  • Autophagy genes act as tumor suppressors in ovarian cancer February 13, 2020
    Shedding light on a decades-old controversy, scientists at the Medical University of South Carolina (MUSC) and University of California at San Diego (UCSD) published findings in PLOS Genetics this month showing that autophagy or "self-eating" genes work against tumors in certain types of ovarian cancer.
  • New gene mutation associated with Fabry cardiomyopathy February 13, 2020
    The A143T variant of the GLA gene is associated with an increased risk of Fabry cardiomyopathy, according to a new study. The variant plays a role in lipid metabolism. According to the researchers, patients carrying the mutation and manifesting changes in the heart should initiate treatment to prevent the disease from progressing. The study, conducted […]
  • CRISPR 'minigene' approach stops genetic liver disease in mice February 12, 2020
    A new CRISPR gene-editing technique prevented a genetic liver disease known to be driven by hundreds of different mutations and improved clinical symptoms in mice, Penn Medicine researchers reported in new proof-of-concept study published online in Science Advances. The findings suggest a promising CRISPR tool that could potentially treat patients with a rare metabolic urea-cycle […]
  • Our digital afterlife February 16, 2020
    It's a problem unique to the 21st century: What happens to your digital self after you die? Social media pages and accounts often turn into memorials when someone dies, giving people a chance to still feel connected to those they've lost. But after we're gone, who owns the information on our pages? Who can access […]
  • Facial expressions don't tell the whole story of emotion February 16, 2020
    Facial expressions might not be reliable indicators of emotion, research indicates. In fact, it might be more accurate to say we should never trust a person's face, new research suggests.
  • Examining how often care, ICU admissions were consistent with treatment-limiting orders near end of life February 16, 2020
    Patients with chronic life-limiting illnesses often have medical orders with treatment limitations in place regarding medical interventions and intensive care unit admissions near the end of their lives. This observational study included about 1,800 patients with such orders who were hospitalized within six months of their death to examine how often care was consistent with […]
  • Factories reimagined February 15, 2020
    Factories in the future will definitely look different than today. As the fourth industrial revolution transforms manufacturing from mass production to mass customization, factory workers will increasingly need to apply new ICT to work remotely, collaborate with robots or use AI-based assistants, to increase their performance while developing further their creative, innovative and improvisational skills. […]
  • The verdict is in: Courtrooms seldom overrule bad science February 15, 2020
    A new, multiyear study published in Psychological Science in the Public Interest (PSPI), a journal of the Association for Psychological Science (APS), finds that only 40% of the psychological assessment tools used in courts have been favorably rated by experts. Even so, lawyers rarely challenge their conclusions, and when they do, only one third of […]